- Home
- SRRK vs SLG Comparison
SRRK vs SLG Comparison
Compare SRRK & SLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- SLG
- Stock Information
- Founded
- SRRK 2012
- SLG 1980
- Country
- SRRK United States
- SLG United States
- Employees
- SRRK N/A
- SLG N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- SLG Real Estate Investment Trusts
- Sector
- SRRK Health Care
- SLG Real Estate
- Exchange
- SRRK Nasdaq
- SLG Nasdaq
- Market Cap
- SRRK 4.2B
- SLG 4.5B
- IPO Year
- SRRK 2018
- SLG 1997
- Fundamental
- Price
- SRRK $43.12
- SLG $65.78
- Analyst Decision
- SRRK Strong Buy
- SLG Hold
- Analyst Count
- SRRK 7
- SLG 16
- Target Price
- SRRK $40.43
- SLG $68.38
- AVG Volume (30 Days)
- SRRK 1.1M
- SLG 931.0K
- Earning Date
- SRRK 11-12-2024
- SLG 01-22-2025
- Dividend Yield
- SRRK N/A
- SLG 4.70%
- EPS Growth
- SRRK N/A
- SLG N/A
- EPS
- SRRK N/A
- SLG N/A
- Revenue
- SRRK N/A
- SLG $920,135,000.00
- Revenue This Year
- SRRK N/A
- SLG N/A
- Revenue Next Year
- SRRK N/A
- SLG $4.08
- P/E Ratio
- SRRK N/A
- SLG N/A
- Revenue Growth
- SRRK N/A
- SLG N/A
- 52 Week Low
- SRRK $6.76
- SLG $41.88
- 52 Week High
- SRRK $46.19
- SLG $82.81
- Technical
- Relative Strength Index (RSI)
- SRRK 57.37
- SLG 42.38
- Support Level
- SRRK $38.72
- SLG $64.71
- Resistance Level
- SRRK $45.15
- SLG $67.09
- Average True Range (ATR)
- SRRK 2.33
- SLG 1.95
- MACD
- SRRK -0.32
- SLG 0.19
- Stochastic Oscillator
- SRRK 73.28
- SLG 58.32
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.